Sign in
Taking peopleNo phase

Tofacitinib in Juvenile Idiopathic Arthritis

Key facts

Who runs it
Consorci Sanitari de l'Alt Penedès i Garraf
Where
Spain7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
58 people, planned
Started
2 Feb 2026
Expected to end
Dec 2027
Type of study
Observational
Treatments tested
  • Tofacitinib
Record updated
28 October 2026

Who can take part

Age
Up to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist
  • Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA
  • Age under 18 years at the time of the treatment indication with tofacitinib

Who cannot take part

  • Participants diagnosed with any of the following conditions:
  • Arthritis associated with inflammatory bowel disease
  • Arthritis associated with another autoimmune disease
  • Reactive arthritis

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.

The group in the trial

  • Tofacitinib

    Patients affected by JIA and treated with tofacitinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Tofacitinib in Patients With Juvenile Idiopathic Arthritis: A Study Based on Real-world Clinical Practice Data.
Record updated
28 October 2026